Persistence support your patients will actually engage with

The problem you already know

Most biologic revenue leakage in IBD isn't missed doses; it's discontinuation. Patients start strong, then drop off between months 3 and 12: side effects they didn't expect, benefit they can't feel yet, cost surprises at reauthorization, or simply losing touch with support they never really engaged with.

Your patient support program is only as good as its engagement rate, and today rates can be pretty abysmal:

• Branded app downloads convert a small fraction of enrolled patients, and retain even fewer

• Hub nurse calls go to voicemail; patients don't answer unknown numbers

• Mailers and portals reach the patients who least need support

The patients most at risk of discontinuing are exactly the ones traditional channels struggle to reach.

Why SMS-first works

Aidy meets patients in the channel they already use. Enrollment takes just a few texts and taps. There is nothing to download, no password to reset, and minimal friction.

• Appless by design. Patients interact entirely through text and secure magic link web pages. Engagement doesn't decay the way app retention does.

• Built for the biologic journey. Injection-day support, side-effect check-ins, “is this working?” expectation-setting during the induction window, refill and reauthorization nudges timed to the moments patients actually quit.

• IBD-native. Aidy is built specifically for Crohn's disease and ulcerative colitis patients: the content, tone, and cadence reflect how this population actually experiences biologic therapy.

• Human where it matters. Structured escalation paths route patients to your hub, nurse line, or HCP when a response signals risk.

What your program gets

• Persistence lift you can measure. Enrollment, engagement rate, time-to-first-dose, refill gap closure, and persistence curves against matched or historical controls, reported in the format your team uses internally.

• A window into why patients discontinue. Structured, patient-reported discontinuation drivers (tolerability, cost, perceived non-response, access friction), which is the data your brand and medical colleagues keep asking for.

• Higher hub program yield. Aidy drives enrollment and re-engagement into the support programs you've already built (copay, PAP, nurse support) rather than competing with them.

Compliance, handled how you'd expect

We know a patient-facing program lives or dies in review.

• Custom adverse event and product complaint workflows with defined intake, documentation, and reporting timelines to your PV team

• TCPA-compliant opt-in consent with documented consent language and full opt-out handling

• HIPAA-aligned infrastructure with BAAs where applicable

• Non-promotional program design with disease-state and support content, structured to survive MLR review